ClinicalTrials.gg
RecruitingNCT06410690AI-CORPSUpdated May 29, 2026

Trustworthy, Integrated Artificial Intelligence Tools for Predicting High-risk CORonary PlaqueS

An observational study in Coronary Artery Disease and Coronary Computed Tomography Angiography, sponsored by Centro Cardiologico Monzino. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Centro Cardiologico Monzino · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
4,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino — 4 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Centro Cardiologico Monzino.

Started
2023
the only one that year
Observational
5 of 11
3 open now
Registered
6th of 11
by date

Among the 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino, this one is the only one that started in 2023, is one of 5 observational ones, and was the 6th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

4 of the 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino, or all of them as a file.
02

Study summary

Coronary artery disease (CAD) is among the leading cause of death and disability. Identification of patients at high risk of cardiovascular events is pivotal. However, current risk stratification based on imaging and known biomarkers is suboptimal. The objective of this proposal is to develop a multicriteria decision model for non-invasive assessment of vulnerable atherosclerotic patients and to evaluate its ability to predict the occurrence of an adverse event in intermediate-to-high risk patients with suspected or known CAD. The planned workflow includes a first step using a retrospective cohort of patients undergoing clinically indicated coronary angiography (CCTA) to develop an integrated application for automatic coronary artery segmentation, quantitative plaque analysis, biomechanics and fluid dynamics, based on machine learning, radiomics and computational analysis approaches and validated against the reference standard for each tool. The second step will apply this new methodology to a larger retrospective cohort of patients with the integration of genomic biomarker assessment to derive the most accurate risk stratification model to properly identify vulnerable patients and vulnerable plaques with respect to outcome. Finally, in the third step, the derived predictive model will be prospectively validated in an independent cohort of patients from an ongoing study (CTP-PRO study) to assess the robustness and accuracy of the proposed solution.

03

Conditions studied

  • Coronary Artery Disease
  • Coronary Computed Tomography Angiography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who performed CCTA and meet all inclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients (age ≥ 18 years) with known or suspected CAD referred for clinically indicated diagnostic evaluation;
  • CCTA performed with state-of-the-art scanner technology, i.e., scanners with more than 64 slices.

Exclusion criteria

Exclusion Criteria:

  • performance of any non-invasive diagnostic test within 90 days before enrolment;
  • low-to-intermediate pre-test likelihood of CAD according to the updated Diamond-Forrester risk model score;
  • acute coronary syndrome;
  • evidence of clinical instability;
  • to contrast agent administration and/or impaired renal function;
  • inability to sustain a breath hold;
  • pregnancy;
  • cardiac arrhythmias;- presence of a pacemaker or implantable cardioverter defibrillator;
  • contraindications to the administration of sublingual nitrates, β-blockers or adenosine;
  • structural cardiomyopathy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
4,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective Cohort

    For the retrospective study, we will enrol 3,000 patients \>18 years old who underwent CCTA and meet all of the inclusion and exclusion criteria, with at least 4-year follow-up. The primary endpoint and patient characteristics will be those of the CTP-PRO study. Since women are less affected by CAD, at a ratio of 35:65, to correct for this expected imbalance we will weight recruitment to obtain relatively sex-balanced cohorts. In subgroups of patients, available data from invasive coronary angiography, FFR and OCT will be collected to help develop, test and refine the diagnostic performance of the automated AI tools.

  • Prospective Cohort

    The cohort will include subjects prospectively enrolled in the CCTA arm of the CTP-PRO study. The subjects will be followed-up for 24 months after CCTA.

06

What researchers measure

Primary outcomes

  1. Creation of an automated integrative artificial intelligence (AI) approach for the stratification of CAD patients and assessment of vulnerable coronary plaques at risk of acute complications

    The main aim of the project develop a multicriteria decision model for the automatic (AI-assisted) non-invasive assessment of vulnerable atherosclerotic patients and evaluate the ability of this model to predict the occurrence of adverse event in intermediate-to-high risk patients with suspected or known CAD. As adverse events, we will consider the annual rate of events, intended as death or hospitalization for revascularization (either CABG or PCI)

    Time frame: January 2026

  2. Quantitative assessment of the atherosclerotic burden and high risk plaque features

    * Extent and severity of coronary atherosclerosis (Leaman Score, number of lesions); * Vulnerability indices: plaque burden (total plaque volume, plaque density), LAP, PR, NRS and SC; * Fluid dynamic indexes of the coronary artery such as the CT derived Fractional Flow Reserve

    Time frame: January 2026

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Nov 2026, 42 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 42 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
May 13, 2024
StartActual
May 22, 2023
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06410690
Lead sponsor
Centro Cardiologico Monzino
Collaborators
Fondazione IRCCS Policlinico San Matteo di Pavia, Politecnico di Milano, Scientific Institute San Raffaele
Responsible party
Sponsor
First posted
May 13, 2024
Start date
May 22, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
May 29, 2026

Study contacts

Gianluca Pontone
Contact
gianluca.pontone@cardiologicomonzino.it
0258002574 ext. +39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion